Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Inc. (NASDAQ: SNGX) has announced encouraging interim results from its HyBryte(TM) program, indicating significant treatment success in early-stage cutaneous T-cell lymphoma (CTCL). The ongoing investigator-initiated study, led by Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program, evaluates the efficacy of extended HyBryte(TM) therapy in patients with early-stage mycosis fungoides. At the 18-week evaluation point, six out of participants showed promising responses, highlighting the potential of HyBryte(TM) as a much-needed treatment option in a field where no new FDA-approved, skin-directed therapies have been introduced in over a decade.

The significance of these findings lies in the limited treatment options available for CTCL patients, especially in the early stages of the disease. Conventional treatments often carry risks, making the search for alternative therapies critical. The interim results from the IIS, conducted in collaboration with the Cutaneous Lymphoma Foundation, suggest that HyBryte(TM) could fill this gap, offering a safer and effective option for patients. For more details on the study, visit https://ibn.fm/IUoEe.